^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
HLA-A*02 positive
i
Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1d
A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy. (PubMed, medRxiv)
The pan-AKT inhibitor, Capivasertib (AZD5363), suppressed some but not all tested PIK3CA -mutated cell lines and one PIK3CA -wt cell line (SiHa). Further research on targeted therapies will improve the prognosis of patients with cervical cancer. Identified 3 molecular subtypes of CC based on PIK3CA and YAP1 amplification status Cervical cell lines with PIK3CA mutation are suppressed by targeted inhibitors PI3K inhibitors Alpelisib/Inavolisib selectively block PIK3CA-mutant cells PIK3CA mutation is associated with higher expression of the checkpoint CD274/PD-L1 PI3K inhibitors cooperate with donor-derived T cells to kill cervical cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • YAP1 (Yes associated protein 1)
|
EGFR mutation • PIK3CA mutation • HLA-A*02 positive
|
Piqray (alpelisib) • Truqap (capivasertib) • Itovebi (inavolisib)
17d
HPV16 E6 TCR T Cells for Cervical Carcinoma (clinicaltrials.gov)
P1/2, N=5, Terminated, TCRCure Biopharma Ltd. | N=18 --> 5 | Trial completion date: Aug 2025 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jan 2026; Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
HLA-A*02 positive
|
cyclophosphamide • fludarabine IV
4ms
Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations. (PubMed, Trends Cancer)
Human leukocyte antigen (HLA)-based immunotherapeutics, such as tebentafusp-tebn and afamitresgene autoleucel, have expanded the treatment options for HLA-A*02-positive patients with rare solid tumors such as uveal melanoma, synovial sarcoma, and myxoid liposarcoma...Last, we emphasize the urgent need for further research to better understand HLA allotype heterogeneity and its influence on tumor immunopeptidome-driven immune responses. We anticipate that these strategies will accelerate the development and implementation of both personalized and broad-spectrum HLA-based immunotherapies, and will ultimately improve cancer treatment across genetically heterogeneous patient populations worldwide.
Review • Journal
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02 positive
|
Kimmtrak (tebentafusp-tebn) • Tecelra (afamitresgene autoleucel)
4ms
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (clinicaltrials.gov)
P1, N=22, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • HLA-A*02 positive
|
Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410
6ms
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer. (PubMed, J Immunother Cancer)
These results provide the preclinical rationale for developing T-cell-based approaches against HERV-K-derived epitopes in ovarian cancer.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
|
HLA-A*02 positive
10ms
Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from LDHC in lung adenocarcinoma. (PubMed, Front Immunol)
P6 (LDHC172-180, YLIGEKLGV) elicited the strongest IFN-γ-secreting cytotoxic T lymphocyte (CTL) response and exhibited potent cytotoxicity against HLA-A2-positive cells with high LDHC expression. LDHC may serve as a targetable biomarker for peptide-based immunotherapy of LUAD.
Journal • IO biomarker
|
IFNG (Interferon, gamma)
|
HLA-A*02 positive
1year
ALLOHA: A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation (clinicaltrials.gov)
P1, N=63, Recruiting, TScan Therapeutics, Inc. | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02 • HLA-A*02 positive
|
melphalan • TSC-100 • TSC-101
over4years
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov)
P1/2, N=11, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Dec 2020 --> Dec 2021
Clinical • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A2 positive • HLA-A*02 positive
|
DPX-E7
over4years
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Nicholas Butowski | Recruiting --> Active, not recruiting | N=30 --> 14
Clinical • Enrollment closed • Enrollment change
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
HLA-A2 positive • HLA-A*02 positive
|
varlilumab (CDX 1127) • Hiltonol (poly-ICLC) • IMA950
Share via
